Optimal timing of coronary angiography and potential intervention in non-ST-elevation acute coronary syndromes

被引:153
作者
Katritsis, Demosthenes G. [1 ]
Siontis, George C. M. [2 ]
Kastrati, Adnan [3 ]
van't Hof, Arnoud W. J. [4 ]
Neumann, Franz-Josef [3 ]
Siontis, Konstantinos C. M. [2 ]
Ioannidis, John P. A. [2 ,5 ,6 ,7 ]
机构
[1] Athens Euroclin, Dept Cardiol, Athens 11521, Greece
[2] Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, Clin Trials & Evidence Based Med Unit, GR-45110 Ioannina, Greece
[3] Tech Univ Munich, Deutsch Herzzentrum, Munich, Germany
[4] Isala Klin, Dept Cardiol, Zwolle, Netherlands
[5] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA
[6] Tufts Univ, Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Boston, MA 02111 USA
[7] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA
关键词
NSTE-ACS; Angiography; Timing; Meta-analysis; GLYCOPROTEIN IIB/IIIA INHIBITORS; MYOCARDIAL-INFARCTION; INVASIVE MANAGEMENT; UNSTABLE ANGINA; METAANALYSIS; STRATEGIES; THERAPY; HETEROGENEITY; IMMEDIATE; STENTS;
D O I
10.1093/eurheartj/ehq276
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims An invasive approach is superior to medical management for the treatment of patients with acute coronary syndromes without ST-segment elevation (NSTE-ACS), but the optimal timing of coronary angiography and subsequent intervention, if indicated, has not been settled. Methods and results We conducted a meta-analysis of randomized trials addressing the optimal timing (early vs. delayed) of coronary angiography in NSTE-ACS. Four trials with 4013 patients were eligible (ABOARD, ELISA, ISAR-COOL, TIMACS), and data for longer follow-up periods than those published became available for this meta-analysis by the ELISA and ISAR-COOL investigators. The median time from admission or randomization to coronary angiography ranged from 1.16 to 14 h in the early and 20.8-86 h in the delayed strategy group. No statistically significant difference of risk of death [random effects risk ratio (RR) 0.85, 95% confidence interval (CI) 0.64-1.11] or myocardial infarction (MI) (RR 0.94, 95% CI 0.61-1.45) was detected between the two strategies. Early intervention significantly reduced the risk for recurrent ischaemia (RR 0.59, 95% CI 0.38-0.92, P = 0.02) and the duration of hospital stay (by 28%, 95% CI 22-35%, P < 0.001). Furthermore, decreased major bleeding events (RR 0.78, 95% CI 0.57-1.07, P = 0.13), and less major events (death, MI, or stroke) (RR 0.91, 95% CI 0.82-1.01, P = 0.09) were observed with the early strategy but these differences were not nominally significant. Conclusion Early coronary angiography and potential intervention reduces the risk of recurrent ischaemia, and shortens hospital stay in patients with NSTE-ACS.
引用
收藏
页码:32 / 40
页数:9
相关论文
共 29 条
[1]  
[Anonymous], IMPUTING SUMMARY STA
[2]  
Bassand JP, 2007, EUR HEART J, V28, P1598, DOI 10.1093/eurheartj/ehm161
[3]   Invasive therapy along with glycoprotein IIb/IIIa inhibitors and intracoronary stents improves survival in non-ST-segment elevation acute coronary syndromes: A meta-analysis and review of the literature [J].
Bavry, AA ;
Kumbhani, DJ ;
Quiroz, R ;
Ramchandani, SR ;
Kenchaiah, S ;
Antman, EM .
AMERICAN JOURNAL OF CARDIOLOGY, 2004, 93 (07) :830-835
[4]   Benefit of early invasive therapy in acute coronary syndromes: A meta-analysis of contemporary randomized clinical trials [J].
Bavry, Anthony A. ;
Kumbhani, Dharam J. ;
Rassi, Andrew N. ;
Bhatt, Deepak L. ;
Askari, Arman T. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 48 (07) :1319-1325
[5]   ong.-term benefits of an early invasive management in acute coronary syndromes depend on intracoronary stenting and aggressive antiplatelet treatment: A metaregression [J].
Biondi-Zoccai, GGL ;
Abbate, A ;
Agostoni, P ;
Testa, L ;
Burzotta, F ;
Lotrionte, M ;
Trani, C ;
Biasucci, LM .
AMERICAN HEART JOURNAL, 2005, 149 (03) :504-511
[6]   Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy [J].
Boden, WE ;
O'Rourke, RA ;
Crawford, MH ;
Blaustein, AS ;
Deedwania, PC ;
Zoble, RG ;
Wexler, LF ;
Kleiger, RE ;
Pepine, CJ ;
Ferry, DR ;
Chow, BK ;
Lavori, PW .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (25) :1785-1792
[7]   Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes:: a meta-analysis of all major randomised clinical trials [J].
Boersma, E ;
Harrington, RA ;
Moliterno, DJ ;
White, H ;
Théroux, P ;
Van de Werf, F ;
de Torbal, A ;
Armstrong, PW ;
Wallentin, LC ;
Wilcox, RG ;
Simes, J ;
Califf, RM ;
Topol, EJ ;
Simoons, ML .
LANCET, 2002, 359 (9302) :189-198
[8]   Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. [J].
Cannon, CP ;
Weintraub, WS ;
Demopoulos, LA ;
Vicari, R ;
Frey, MJ ;
Lakkis, N ;
Neumann, FJ ;
Robertson, DH ;
DeLucca, PT ;
DiBattiste, PM ;
Gibson, CM ;
Braunwald, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (25) :1879-1887
[9]   Early invasive versus selectively invasive management for acute coronary syndromes [J].
de Winter, RJ ;
Windhausen, F ;
Cornel, JH ;
Dunselman, PHJM ;
Janus, CL ;
Bendermacher, PEF ;
Michels, HR ;
Sanders, GT ;
Tijssen, JGP ;
Verheugt, FWA .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (11) :1095-1104
[10]   A validated prediction model for all forms of acute coronary syndrome - Estimating the risk of 6-month postdischarge death in an international registry [J].
Eagle, KA ;
Lim, MJ ;
Dabbous, OH ;
Pieper, KS ;
Goldberg, RJ ;
Van de Werf, F ;
Goodman, SG ;
Granger, CB ;
Steg, PG ;
Gore, JM ;
Budaj, A ;
Avezum, A ;
Flather, MD ;
Fox, KAA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (22) :2727-2733